Literature DB >> 1806029

Emerging differences between 5-HT3 receptor antagonists.

H E Marr1, P T Davey, A J Bartlett.   

Abstract

A brief review is presented of some recently described 5-HT3 receptor antagonists. These antagonists are primarily targeted for use as anti-emetics. However, evidence is emerging that there are differences in their basic pharmacology. This evidence is reviewed in terms of the selectivity of the antagonists in binding studies and also of their efficacy in emesis and gastric emptying. The possibility that these differences may translate into meaningful clinical differences between the available 5-HT3 receptor antagonists in their use as anti-emetics is also discussed.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1806029     DOI: 10.1097/00001813-199112000-00001

Source DB:  PubMed          Journal:  Anticancer Drugs        ISSN: 0959-4973            Impact factor:   2.248


  3 in total

1.  Pharmacological characterization of RS 25259-197, a novel and selective 5-HT3 receptor antagonist, in vivo.

Authors:  R M Eglen; C H Lee; W L Smith; L G Johnson; R Clark; R L Whiting; S S Hegde
Journal:  Br J Pharmacol       Date:  1995-02       Impact factor: 8.739

Review 2.  Are there differences among the serotonin antagonists?

Authors:  M Tonato; F Roila; A Del Favero
Journal:  Support Care Cancer       Date:  1994-09       Impact factor: 3.603

3.  Effect of metoclopramide, ondansetron and granisetron on aldosterone secretion in man.

Authors:  D K Sommers; J R Snyman; M van Wyk
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.